Total trials
1,120
Active
310
Phase 3
48
Total enrollment
31,547,258
Pipeline matrix
Showing 40 of 41 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Tranexamic acid | — | — | — | — | — | 1 | |
| Apixaban | — | — | — | — | — | 1 | |
| Warfarin | — | — | — | — | — | 1 | |
| ALK Alutard SQ Dog | — | — | — | — | — | 1 | |
| Gardasil 9 2 dose regimen | — | — | — | — | — | 1 | |
| Self administred propofol | — | — | — | — | — | 1 | |
| Nurse assisted propofol sedation | — | — | — | — | — | 1 | |
| Patient controlled analgesia | — | — | — | — | — | 1 | |
| Standard medical treatment | — | — | — | — | — | 1 | |
| Diclofenac | — | — | — | — | 2 | ||
| Saline solution | — | — | — | — | — | 2 | |
| Enzalutamide Oral | — | — | — | — | — | 1 | |
| Abiraterone Oral | — | — | — | — | — | 1 | |
| Carboplatin | — | — | — | — | — | 1 | |
| Cabazitaxel 60 mg Solution for | — | — | — | — | — | 1 | |
| Docetaxel Injectable Solution | — | — | — | — | — | 1 | |
| Radium Chloride Ra-223 | — | — | — | — | — | 1 | |
| Niraparib plus Abiraterone acetate plus Prednisone | — | — | — | — | — | 1 | |
| Capivasertib plus Docetaxel | — | — | — | — | — | 1 | |
| Apalutamide | — | — | — | — | — | 1 | |
| Darolutamide | — | — | — | — | — | 1 | |
| Mesh reinforcement | — | — | — | — | — | 1 | |
| Individual dose of tamoxifen | — | — | — | — | — | 1 | |
| Standard adjuvant therapy of tamoxifen | — | — | — | — | — | 1 | |
| Ropivacaine | — | — | — | — | — | 1 | |
| Metformin | — | — | — | 3 | |||
| Botulinum toxin type A | — | — | — | — | 2 | ||
| BOOST cells | — | — | — | — | — | 1 | |
| CellProtect | — | — | — | — | — | 1 | |
| Isatuximab | — | — | — | — | — | 1 | |
| Eplerenone | — | — | — | — | — | 1 | |
| Isotonic saline 0,9% | — | — | — | — | — | 1 | |
| Immunomodulation | — | — | — | — | — | 1 | |
| prednisolone | — | — | — | — | — | 1 | |
| Saline | — | — | — | — | — | 1 | |
| Obesity medication with liraglutide or semaglutide | — | — | — | — | — | 1 | |
| Medical Therapy | — | — | — | — | — | 1 | |
| Pioglitazone 45 mg | — | — | — | — | — | 1 | |
| Empagliflozin 25 MG | — | — | — | — | — | 1 | |
| Semaglutide 7 MG | — | — | — | — | — | 1 |
1 more active programs hidden
Next readouts
- 2005-04
- 2024-01-10
- 2025-06
- 2025-06-30
- 2025-12
- 2026-01-30
- 2026-08-30
- 2026-09-01
- 2026-12
- 2026-12-31
Top conditions
- Depression26
- Stroke21
- Anxiety20
- Insomnia15
- Anxiety Disorders15
- Obesity14
- Atrial Fibrillation14
- Prostate Cancer13
Frequently asked questions about Karolinska Institutet
- How many clinical trials does Karolinska Institutet have on ClinicalTrials.gov?
- Karolinska Institutet is listed as the lead sponsor on 1,120 clinical trials in ClinicalTrials.gov, 310 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Karolinska Institutet's trials are in Phase 3?
- 48 of Karolinska Institutet's trials are in Phase 3, spread across 41 active drug programs.
- What therapeutic areas does Karolinska Institutet focus on?
- Karolinska Institutet's most-studied conditions on ClinicalTrials.gov are Depression, Stroke, Anxiety, Insomnia, Anxiety Disorders.
- When are Karolinska Institutet's next clinical trial readouts?
- Karolinska Institutet has 10 upcoming primary-completion readouts tracked here; the soonest is “Longitudinal Assessment of Clinical Course and BIOmarkers in Severe Chronic AIRway Disease”, expected around 2005-04.